Medical Condition News

RSS

United Therapeutics completes enrollment in FREEDOM-C(2) UT-15C study in pulmonary arterial hypertension

United Therapeutics Corporation announced today that enrollment in its FREEDOM-C(2) registration trial was completed on March 18, 2011.

21 Mar 2011

First clinical use of GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface on lower profile delivery system

W. L. Gore & Associates (Gore) today reported the first clinical use in the U.S. of the GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface on a lower profile delivery system. The GORE VIABAHN Device is designed to percutaneously treat Superficial Femoral Artery (SFA) and iliac peripheral artery disease by relining the native vessel.

21 Mar 2011

Shire announces FDA PDUFA date for FIRAZYR NDA in treatment of acute attacks of hereditary angioedema

Shire plc, the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) date of August 25, 2011 for the review of the New Drug Application (NDA) for FIRAZYR(R) (icatibant) for the treatment of acute attacks (Types I and II) of hereditary angioedema (HAE). This 6 month review timeline is consistent with review as a Class II resubmission.

21 Mar 2011

Study on mandibular changes produced by skeletal anchorage assisted orthopedic traction

Today, during the 89th General Session & Exhibition of the International Association for Dental Research, held in conjunction with the 40th Annual Meeting of the American Association for Dental Research and the 35th Annual Meeting of the Canadian Association for Dental Research, lead researcher T. Nguyen will hold an oral presentation on a study titled "Mandibular Changes Produced by Skeletal Anchorage Assisted Orthopedic Traction."

21 Mar 2011

Physical ill-health reduces life expectancy of people with severe mental illness

Physical ill-health is rife among the severely mentally ill in Britain, according to new research published today by the University of East Anglia (UEA).

21 Mar 2011

XenoPort reports preliminary top-line results from arbaclofen placarbil Phase 2b clinical trial in GERD

XenoPort, Inc. announced today preliminary top-line results from a Phase 2b clinical trial of arbaclofen placarbil (also known as AP) as adjunctive therapy in patients with gastroesophageal reflux disease (GERD) who do not experience complete relief of GERD symptoms while being treated with proton pump inhibitors (PPI).

21 Mar 2011

Organic, non-toxic, biodegradable nanoparticle uses light and heat to treat cancer

A team of scientists from Princess Margaret Hospital have created an organic nanoparticle that is completely non-toxic, biodegradable and nimble in the way it uses light and heat to treat cancer and deliver drugs.

21 Mar 2011

Ethnicity, depression, lack of exercise are major risk factors for chronic fatigue syndrome

Chronic fatigue syndrome (CFS) is characterized by unexplained and debilitating tiredness and is associated with headaches, disrupted sleep, muscle pain and difficulty in concentrating. New research published by BioMed Central's open access journal BMC Medicine shows that ethnicity, depression, lack of exercise or social support, and social difficulties are major risk factors for CFS.

21 Mar 2011

Positive results from GDC-0449 Phase II clinical trial in advanced basal cell carcinoma

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced a positive outcome from a pivotal Phase II clinical trial conducted by Roche and Genentech, Curis' collaborator and a wholly owned member of the Roche Group, of GDC-0449, a first-in-class hedgehog pathway inhibitor, in patients with advanced basal cell carcinoma (BCC).

21 Mar 2011

Researchers baffled with increase in migraine rates

Migraine rates in a comprehensive Norwegian health study have climbed by 1% in a decade -- that may not sound like much, but in the Norwegian context, it means 45,000 more migraine sufferers -- and if the trend were to hold for the European Union, that would be an additional 5 million more people plagued by migraines. Researchers at the Norwegian University of Science and Technology (NTNU) are baffled by the cause of this trend.

21 Mar 2011

Tiny Locked Nucleic Acid-based compounds inhibit entire disease-associated microRNA families

A study published online in this week's Nature Genetics demonstrates that tiny Locked Nucleic Acid (LNA)-based compounds developed by Santaris Pharma A/S can inhibit entire disease-associated microRNA families. This provides a potential new approach for treating a variety of diseases including cancer, viral infections, cardiovascular and muscle diseases.

21 Mar 2011

Researchers discover 'broad spectrum' cancer suppressor gene

Portuguese researchers have discovered a "broad spectrum" cancer suppressor gene - called LRP1B - which acts by removing proteins crucial for cancer development from the tumour environment. The fact that LRP1B does not act on the tumour itself (in this study thyroid tumours) but, instead, on molecules which are known to be important to many different cancers is what makes it so interesting.

21 Mar 2011

$CTI commences pixantrone PIX-R trial in relapsed/refractory diffuse large B-cell lymphoma$

CTI commences pixantrone PIX-R trial in relapsed/refractory diffuse large B-cell lymphoma

Cell Therapeutics, Inc. today announced that it has initiated its randomized pivotal trial of pixantrone for the treatment of relapsed/refractory diffuse large B-cell lymphoma ("DLBCL").

21 Mar 2011

Onset of chronic pain more often reported following a traffic accident

Individuals with poorer health or psychological issues may be prone to developing chronic widespread pain following a traumatic event. This new research, published in Arthritis Care & Research, a peer-reviewed journal of the American College of Rheumatology (ACR), found that the onset of chronic pain was more often reported following a traffic accident than from other physically traumatic triggers.

21 Mar 2011

Genentech's vismodegib Phase II clinical study in advanced basal cell carcinoma meets primary endpoint

Genentech, a member of the Roche Group, today announced that a pivotal Phase II clinical study of its investigational Hedgehog Pathway Inhibitor, vismodegib (RG3616/GDC-0449), showed positive results in people with advanced basal cell carcinoma (aBCC), a particularly severe and debilitating form of skin cancer.

21 Mar 2011

Asthma an diabetes go hand in hand: Research

A new study has found that people with asthma may have a higher risk of developing diabetes and heart disease. The study looked at the relationship between asthma and four other inflammatory conditions.

21 Mar 2011

JCCF event honors Showtime Networks President with Humanitarian Award

The Jonsson Cancer Center Foundation at UCLA hosts its 16th annual Taste for a Cure Friday, April 15, 2011 at the Beverly Wilshire Hotel. This year's event honors Showtime Networks President of Entertainment, David Nevins, with the Gil Nickel Humanitarian Award.

19 Mar 2011

Researcher to present study on validation of salivary-biomarkers for pSS patients

Saturday, March 19, during the 89th General Session & Exhibition of the International Association for Dental Research, held in conjunction with the 40th Annual Meeting of the American Association for Dental Research and the 35th Annual Meeting of the Canadian Association for Dental Research, lead researcher A.N.M. Nazmul-Hossaini will hold an oral presentation on a study titled "Validation of Salivary-Biomarkers for Sj-gren's Syndrome Detection in US Population."

19 Mar 2011

CHMP recommends approval of Centralized Marketing Authorization for Cinryze

ViroPharma Incorporated today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion at its plenary meeting in March 2011 recommending approval of a Centralized Marketing Authorization for Cinryze (C1 inhibitor [human]) in adults and adolescents with hereditary angioedema for routine prevention, pre-procedure prevention and acute treatment of angioedema attacks.

19 Mar 2011

Insight into hereditary diseases

Hereditary diseases such as epilepsy or various coordination disorders may be caused by changes in nerve cells of the cerebellum, which do not set in until after birth. This is reported by Bochum's neuroscientists in the Journal of Neuroscience.

19 Mar 2011

Medical Condition News

United Therapeutics completes enrollment in FREEDOM-C(2) UT-15C study in pulmonary arterial hypertension

First clinical use of GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface on lower profile delivery system

Shire announces FDA PDUFA date for FIRAZYR NDA in treatment of acute attacks of hereditary angioedema

Study on mandibular changes produced by skeletal anchorage assisted orthopedic traction

Physical ill-health reduces life expectancy of people with severe mental illness

XenoPort reports preliminary top-line results from arbaclofen placarbil Phase 2b clinical trial in GERD

Organic, non-toxic, biodegradable nanoparticle uses light and heat to treat cancer

Ethnicity, depression, lack of exercise are major risk factors for chronic fatigue syndrome

Positive results from GDC-0449 Phase II clinical trial in advanced basal cell carcinoma

Researchers baffled with increase in migraine rates

Tiny Locked Nucleic Acid-based compounds inhibit entire disease-associated microRNA families

Researchers discover 'broad spectrum' cancer suppressor gene

CTI commences pixantrone PIX-R trial in relapsed/refractory diffuse large B-cell lymphoma

Onset of chronic pain more often reported following a traffic accident

Genentech's vismodegib Phase II clinical study in advanced basal cell carcinoma meets primary endpoint

Asthma an diabetes go hand in hand: Research

JCCF event honors Showtime Networks President with Humanitarian Award

Researcher to present study on validation of salivary-biomarkers for pSS patients

CHMP recommends approval of Centralized Marketing Authorization for Cinryze

Insight into hereditary diseases

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Latest News